Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
14C-JNJ-39823277 · 1 trial · 1 indication
The Tmax is defined as actual sampling time to reach maximum observed analyte concentration.
The AUClast is area under the plasma concentration-time curve from time zero to the last quantifiable concentration.
The AUC(0-infinity) is area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of Area under Curve (AUC) last and C(last)/lambda(z), in which C(last) is the last observed quantifiable concentration.
T1/2 is the time measured for the plasma concentration to decrease by one-half of its original concentration. It is associated with the terminal rate-constant (lambda\[z\]) of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).
| Arm | Type | Description |
|---|---|---|
| 14C-JNJ-39823277 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| 14C-JNJ-39823277 | DRUG | Participants will receive a single oral dose of 25 mg 14C-JNJ-39823277 as a 50-mL solution. |
Inclusion Criteria: * Body mass index (BMI) between 20 and 30 kg/m2 (BMI will be calculated as weight \[kg\]/square of height \[square meter\]) * Had consistent bowel movement habit (approximately once per day) within 30 days before dosing * No clinically significant laboratory and electrocardiogra...
14C-JNJ-39823277 is an investigational small molecule developed by Johnson & Johnson. It is a carbon-14 radiolabeled form of the compound JNJ-39823277, used in a Phase 1 study to evaluate absorption, metabolism, and excretion in healthy male participants. The therapeutic indication has not been disclosed.
14C-JNJ-39823277 is being developed by Johnson & Johnson, which trades on the New York Stock Exchange under the ticker JNJ. The compound is an investigational small molecule studied in a single Phase 1 clinical trial conducted in Belgium.
14C-JNJ-39823277 is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are currently listed. The study enrolled six healthy male participants and was conducted in Belgium.
14C-JNJ-39823277 was evaluated in a single Phase 1 trial, NCT02049697, titled A Study to Evaluate of the Absorption, Metabolism, and Excretion of 14C-JNJ-39823277 in Healthy Male Participants. The trial enrolled six healthy male volunteers in Belgium and has been completed.
14C-JNJ-39823277 is an investigational compound with no disclosed therapeutic indication. Its only recorded clinical study was a Phase 1 absorption, metabolism, and excretion trial in healthy male participants, not a study in patients with a specific disease.